慢性肾脏病中的脂质管理：《改善全球肾脏病预后组织 2013 年临床实践指南》概要。
Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline.
出版信息
Ann Intern Med. 2014 Feb 4;160(3):182. doi: 10.7326/M13-2453.
DESCRIPTION
The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed a clinical practice guideline in 2013 on lipid management and treatment of all adults and children with chronic kidney disease (CKD). All forms of CKD are included (non-dialysis-dependent, dialysis-dependent, and kidney transplant recipients).
METHODS
The KDIGO Lipid Guideline Development Work Group defined the scope of the guideline, gathered evidence, determined topics for systematic review, and graded the quality of evidence that had been summarized by an evidence review team. Searches of the English-language literature were conducted through August 2011 and supplemented by targeted searches through June 2013. Final modification of the guidelines was informed by the KDIGO Board of Directors and a public review process involving registered stakeholders.
RECOMMENDATIONS
The full guideline includes 13 recommendations; a key element was the recommendation for statin or statin with ezetimibe treatment of adults aged 50 years or older with estimated glomerular filtration rates less than 60 mL/min/1.73 m2 but not treated with long-term dialysis or kidney transplantation. This synopsis focuses on 8 recommendations pertinent to assessment of lipid status and treatment with a statin-based regimen in adults.
描述
肾脏疾病：改善全球预后（KDIGO）组织于 2013 年制定了关于血脂管理和治疗所有慢性肾脏病（CKD）成人和儿童的临床实践指南。所有形式的 CKD 均包括在内（非透析依赖、透析依赖和肾移植受者）。
方法
KDIGO 血脂指南制定工作组界定了指南的范围，收集证据，确定系统评价的主题，并对由证据审查小组总结的证据质量进行分级。对英文文献的检索工作进行到 2011 年 8 月，并通过 2013 年 6 月的有针对性检索进行补充。指南的最终修订由 KDIGO 理事会和一个涉及注册利益相关者的公开审查过程提供信息。
建议
完整的指南包括 13 项建议；一个关键要素是推荐他汀类药物或他汀类药物联合依折麦布治疗年龄在 50 岁及以上、估计肾小球滤过率（eGFR）低于 60mL/min/1.73m2 但未接受长期透析或肾移植的成年人。这篇综述主要关注与成人血脂状况评估和基于他汀类药物治疗方案相关的 8 项建议。
Zotero 插件